0.64
0.64 (0%)
As of Feb 14, 2025
Ovid Therapeutics Inc. [OVID]
Source:
Company Overview
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain conditions with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neural hyper-excitation and alleviating the most impactful patient symptoms.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | 212-776-4381 |
| Industry | manufacturing |
| CEO | Jeremy M. Levin, Dphil, Mb Bchir |
| Website | www.ovidrx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.6 |
| Operating Profit | $-61.9 |
| Net Income | $-26.4 |
| Net Cash | $-0.7 |
Profit Ratios
| Gross Margin | $0.6 |
| Operating Margin | -10,933.8 |
| Profit as % of Revenues | -2.1% |
| Profit as % of Assets | -22.4% |
| Profit as % of Stockholder Equity | -38.7% |
Management Effectiveness
| Return on Equity | -38.7% |
| Return on Assets | -28.7% |
| Turnover Ratio | 0.5% |
| EBITA | $-61.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $92.2 |
| Total Liabilities | $23.9 |
| Operating Cash Flow | $-56 |
| Investing Cash Flow | $54.6 |
| Financing Cash Flow | $0.6 |
